<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04830202</url>
  </required_header>
  <id_info>
    <org_study_id>C20-503</org_study_id>
    <nct_id>NCT04830202</nct_id>
  </id_info>
  <brief_title>Expanded Access to Telisotuzumab Vedotin</brief_title>
  <official_title>Expanded Access to Telisotuzumab Vedotin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <brief_summary>
    <textblock>
      This is an expanded access program (EAP) for eligible participants. This program is designed&#xD;
      to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency.&#xD;
      Availability will depend on territory eligibility. A medical doctor must decide whether the&#xD;
      potential benefit outweighs the risk of receiving an investigational therapy based on the&#xD;
      individual patient's medical history and program eligibility criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Non-Small Cell Lung Cancer (NSCLC)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telisotuzumab vedotin</intervention_name>
    <description>Intravenous Infusion</description>
    <other_name>ABBV-399</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant must not be eligible for a telisotuzumab vedotin clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer (NSCLC)</keyword>
  <keyword>Telisotuzumab vedotin</keyword>
  <keyword>ABBV-399</keyword>
  <keyword>Expanded Access</keyword>
  <keyword>Pre-approval Access</keyword>
  <keyword>Compassionate Use</keyword>
  <keyword>Special Access Program</keyword>
  <keyword>Named Patient Basis</keyword>
  <keyword>Special Access Scheme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

